CD274 and neoplasm: PD-L1 expression in tumor cells, assessed using immunohistochemistry (IHC) assays, has evolved alongside advances in ICI therapy as a key biomarker for predicting the efficacy of PD-1/PD-L1 inhibitors in advanced NSCLC.